

Positive Effect of Magnesium Orotate Therapy in Hypertensive Heart Disease

Kisters K^{1,2*}, Gremmler B¹, Schmidt J³, Gröber U² and Tokmak F⁴

¹Med Clinic I, St. Anna-Hospital & ESH Excellence Centre, Herne, Germany

²Akademie für Mikronährstoffmedizin, Essen, Germany

³Pharmakologie und Toxikologie Uni Dresden, Dresden, Germany

⁴MVZ Gelsenkirchen-Buer, Gelsenkirchen, Germany

Abstract

According to the results of the MACH study additional magnesium orotate therapy has shown a positive effect on life expectancy and quality of life in patients with severe forms of heart insufficiency. Both magnesium and orotate can be cardio protective. In the presented data here additional magnesium orotate therapy was tested in 11 patients with hypertensive heart disease NYHA III-IV as compared to 10 patients with hypertensive heart disease NYHA II-IV as controls. Additional magnesium orotate therapy was 4500 mg magnesium orotate daily for 1 week. NTproBNP levels decreased significantly in the magnesium orotate group versus controls ($p < 0.01$). Under therapy quality of life improved significantly as well. Kidney function remained stable in the normal range.

In conclusion an additional therapy with magnesium orotate is safe and can be of additional benefit in hypertensive heart disease with insufficiency.

There is an improvement in quality of life and life expectancy in heart insufficiency under an additional magnesium orotate therapy.

Keywords: Magnesium; Orotate; Heart insufficiency

Introduction

It is well known that magnesium deficiency plays an important role in the pathogenesis of essential hypertension [1-25]. Likewise the efficacy of an oral therapy with magnesium is well documented in hypertension and borderline hypertension. Also in lipid disorders and in the development of atherosclerosis or cancer magnesium deficiency is commonly involved [26-31].

The combination of hypertension and diabetes mellitus is more severe with involvement of magnesium deficiency [9,10,27,32-34].

The MACH study showed a positive effect of an oral therapy with magnesium orotate in patients with heart failure NYHA IV. Patients who were treated had an enhanced life expectancy compared to the controls. In the same way the quality of life improved significantly over the course of one year in the majority of patients [35]. Similar results were obtained by Geiss et al. [36], showing the positive effect of magnesium orotate in patients with coronary heart disease.

Because of these pathophysiological interrelationships and the past studies we conducted the following study.

Patients and Methods

We performed an observational study with 11 patients who were suffering from hypertensive heart disease and heart failure NYHA III-IV. Additionally they were treated with magnesium orotate whereas 10 patients with heart failure served as controls. The clinical data can be seen in Table 1.

Statistically the groups were not significantly different concerning age and gender distribution. All patients had healthy kidneys. Severe side effects under the additive magnesium therapy did not occur.

We measured NTproBNP before the beginning and at the end of the therapy of one week duration. The verum group was treated additionally with 3 x 3 tablets Magnerot CLASSIC N (300 mg magnesium/d). Furthermore the patients underwent ECG and long-term ECG (holter) analysis. The serum-creatinine was measured before and after the treatment.

	+ Mg-orotate	- Mg-orotate
Gender (m/f)	6/5	5/5
Age (years)	67.2 ± 5.6	69.7 ± 7.1
Serum creatinine (mg/dl)	1.0 ± 5.6	1.1 ± 0.2
Side effects	2 (soft stools)	
Life quality		
(improved)	7	4
(deteriorated)	1	2

Table 1: Clinical data study of 11 patients with heart failure with additional magnesium orotate therapy compared with 10 controls with heart failure (mean +/- standard deviation).

The statistical analysis was performed with Wilcoxon test. The measured values were mean +/- standard deviation, $p < 0.05$ was determined as statistically significant.

All patients gave their written consent for this observational study.

Results

The 11 patients with hypertensive heart disease NYHA III-IV who received magnesium orotate therapy measured a statistically significant reduction of their NTproBNP blood values. This reduction was considerably higher in comparison to the control group without additive magnesium orotate therapy.

NTproBNP blood values of the magnesium treated group were 4761 +/- 2284 pg/ml pre therapy and 3516 +/- 2114 pg/ml post therapy

***Corresponding author:** Kisters K, St. Anna-Hospital, Hospitalstr. 19, D-44649 Herne, Germany, Tel: +49 2325 9862100; E-mail: klaus.kisters@elisabethgruppe.de

Received September 06, 2017; **Accepted** September 18, 2017; **Published** September 25, 2017

Citation: Kisters K, Gremmler B, Schmidt J, Gröber U, Tokmak F (2017) Positive Effect of Magnesium Orotate Therapy in Hypertensive Heart Disease. Metabolomics (Los Angel) 7: 195. doi:10.4172/2153-0769.1000195

Copyright: © 2017 Kisters K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

($p < 0.01$). The control group pre therapy measured 4331 ± 2688 pg/ml. After the therapy the results were 4091 ± 2491 pg/ml. There was also a reduction of NTproBNP in the control group. However the results concerning the reduction of NTproBNP in the magnesium orotate treated group were significantly lower ($p < 0.01$).

The serum creatinine levels did not change significantly in the control group as well as in the magnesium treated group compared to the pretreated values. All results were within normal range. In the magnesium treated group two patients complained about slight side effects concerning smooth stool. The results of the questionnaire of life quality concluded that 7 of 11 patients in the magnesium treated group stated an improvement of their life quality, whereas 1 patient complained of worsening of his life quality.

In the group, that was treated without magnesium 4 patients stated an improvement and 2 patients a worsening of their life quality.

Discussion

As it is known recently, changes in magnesium balance in hypertension have gathered fair amounts of attention.

Many basic studies have shown that magnesium deficiency might be involved in the development of essential hypertension or borderline hypertension [14-25,37-41].

In intensive care medicine you often see magnesium deficiency in patients which is a corresponding risk factor for their prognosis [42]. In the same way magnesium deficiency may be induced or veiled in the treatment of hypertension, e.g. with diuretics. Reasons of magnesium deficiency are manifold.

The most important pathophysiological mode of action is its calcium antagonistic effect. Furthermore there is a sodium-magnesium-antiport. In recent years autonomous magnesium channels were found in the gut, then, 2 years ago they were found in the kidney as well. In the development of hypertension first analyses of mutations of these TRPM6 and 7 channels in this regard are available [43]. Table 2 shows the reasons of magnesium deficiency.

Drug interaction often may induce magnesium deficiency as well. This Table 3 shows drugs that can trigger QT-prolongation and Torsade-de-pointes tachycardia, whereby a magnesium deficiency may worsen it [41]. Table 4 shows contraindications and side effects of magnesium therapy.

A. Increased Mg⁺⁺ sequestration from extracellular space
1. increased Mg ⁺⁺ -intake in bone
2. Mg ⁺⁺ -precipitation in tissue
3. increased Mg ⁺⁺ -intake in intracellular space
4. respiratory alkalosis
B. Increased renal Mg⁺⁺ -excretion
1. diuretics
2. expansion of the extracellular space
3. drugs
4. congenital defects of the tubular mg ⁺⁺ -reabsorption
C. Decreased intestinal Mg⁺⁺ -absorption
1. malnutrition/subnutrition
2. malabsorption
3. parenteral feeding
D. Alcoholism

Table 2: Causes of magnesium deficiency.

Antiarrhythmic agents	Quinidine, Sotalol, Amiodarone, Flecainide
Antibiotics	Erythromycin, Clarithromycin, Levofloxacin, Moxifloxacin, Pentamidine
Antihistamines	Diphenhydramine, Clemastine
Antidepressants	Amitriptyline, Imipramine, Desipramine, Maprotiline, Fluoxetine, Sertraline, Citalopram
Neuroleptics	Haloperidol, Pimozide, Thioridazine
Anti-malarial tablets	Quinine, Chloroquine
Analgesics	Levomethadone
Cytostatic drugs	Arsenic trioxide
Antiemetic drugs	Domperidone

Table 3: Drugs that trigger QT-elongation and Torsade-de-pointes tachycardia.

Contraindications	
Oral administration	advanced renal insufficiency (dosage adaptation should be considered in case of impaired kidney function)
Parenteral administration	AV block or other cardiac conduction disorders
	advanced renal insufficiency (dosage adaptation and control of magnesium-serum-concentration should be considered in case of impaired kidney function)
Adverse reactions	
Oral administration	even at higher dosages no severe side effects: soft stools (often just temporary) are possible
Parenteral administration	Parenteral administration
	cardiac conduction disorders of sinus- and AV nodes
	peripheral vasodilatation (flush)
	sweating
	nausea and vomiting

Table 4: Contraindications and adverse reactions of magnesium therapy.

In cardiology an intact magnesium balance is of particular interest. The MACH study could show the beneficial use of magnesium orotate as adjuvant therapy in patients on optimal treatment for severe congestive heart failure in a follow-up study of 1 year [35]. It is also well known, that magnesium has a significant value in the treatment of cardiac arrhythmia, Torsade-de-pointes tachycardia responds especially well to the intravenous administration of magnesium sulfate [26,41,44-50]. There is however scant data for the treatment of heart failure with an additional magnesium therapy. The MACH study, cited above, which showed a positive effect in severe cases of heart failure, served for this study as status [35].

In this already short observation period of 1 week with additional daily treatment with 300 mg magnesium orotate, values of NTproBNP decreased markedly and statistically significant which is known as a marker to assess heart failure (Figure 1). Furthermore most of the treated patients stated a distinct clinical improvement of their complaints.

As magnesium orotate is used in the presented study, we closely monitored kidney function because of the orotate component.

None of the magnesium orotate treated patients showed in the course a change of serum creatinine compared to the pretreated values. Already during the 1990s a positive effect of orotate in heart failure could be shown in investigations with animal model. Here, stabilization of cardiac cell functions was described. It could additionally be demonstrated that orotic acid could distinctly improve the metabolism of myocardial cells. In this way the metabolism of glycogen in the hypertrophic heart could be markedly improved by administration of orotate [35,45].




Figure 1: NTproBNP-values (mean+/- standard deviation) of 11 patients with heart failure before and after additive application of magnesium orotate (p<0.01).

In general	nervousness, inner anxiety, fear, depression, dysmenorrhea, hyperactivity, headaches, noise sensitivity, low level of stress tolerance, sleep disorders
Musculature	neuromuscular hyperexcitability (muscle cramps, muscle tensions), fasciculations (isolated muscle twitching), eyelid twitch, cramps of foot sole, -facial muscles, -masticatory muscles (trismus), -calves, tetany caused by magnesium deficiency
Nerves/CNS	migraine, nervousness, increased responsiveness of NMDA receptors to excitatory neurotransmitter, paresthesia (abnormal sensations such as tingle or numbness), tremor
Gastrointestinal tract	colicky spasms, obstipation
Cardiovascular system	endothelial dysfunction, heart rhythm disorders (coronary spasms, ventricular extrasystoles, tachycardias), high blood pressure, vascular spasm, impairment of myocardial pump function, heart failure, enhanced intolerance to cardiac glycosides
Metabolism	Dyslipoproteinemia (increase of triglycerides, total cholesterol), reduction of glucose tolerance, increase in HbA1c, deterioration of insulin sensitivity, increased risk of metabolic syndrome and type 2 diabetes mellitus, increased risk of diabetic complications (e.g. diabetic polyneuropathy, nephropathy and retinopathy) disorder of bone and vitamin d metabolism, recurrence of calcium oxalate kidney stones
Pregnancy	pregnancy complications (e.g. abortion, premature contractions, increased premature births rate, reduced birth weight), pre-eclampsia (gestosis with increased blood pressure and proteinuria)
Telomere	premature shortening (time ageing)

Table 5: Symptoms of magnesium deficiency [43].

Newman and his coworkers described an improvement of “beat-output-index”, even after myocardial infarction, when the patients were treated with additional orotic acid. A statistically significant improvement of beat-output compared to myocardial infarction group who were not treated with additional orotic acid was shown.

In summary here the conducted study shows that a therapy with magnesium orotate can be considered as a safe mode of treatment for patients with hypertensive heart disease and heart failure NYHA III-IV. The patients showed markedly improved NTproBNP values already after one week of treatment [51]. This was, from a statistical standpoint, significantly better than the group without treatment. Furthermore a reduction in clinical complaints was seen. The kidney function was stable at all times. Severe cardiac arrhythmia did not occur in the course of this observational study. Table 5 shows the symptoms of magnesium deficiency.

To summarize, the presented study shows that the treatment with magnesium orotate has significant value in the treatment of patients with heart failure regarding life expectancy, life quality as well as incidence of cardiac arrhythmia [52]. In either case magnesium deficiency should be taken into consideration for high-risk patients.

References

1. Altura BM, Altura BT (1984) Interactions of Mg and K on blood vessels-aspects in view of hypertension. Review of present status and new findings. *Magnesium* 3: 175-194.
2. Altura BM, Altura BT (1991) Cardiovascular risk factors and magnesium: relationships to atherosclerosis, ischemic heart disease and hypertension. *Magnesium and Trace Elements* 10: 182-192.
3. Barbagallo M, Belvedere M, Dominguez LJ (2009) Magnesium homeostasis and aging. *Magnesium Res* 22: 235-256.
4. Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M (2010) Oral magnesium supplementation improves vascular function in elderly diabetic patients. *Magnesium Res* 3: 131-137.
5. Dyckner T, Wester PO (1983) Effect of magnesium on blood pressure. *Br Med J (Clin Res Ed)* 286: 1847-1849.
6. Gröber U (2007) Antihypertensives and magnesium-update. *Trace Elem Electrolyt* 26: 15-16.
7. Grober G, Kisters K (2012) Influence of drugs on vitamin D and calcium metabolism. *Dermatoendocrinol* 4: 158-166.
8. Gröber U, Schmidt J, Kisters K (2015) Magnesium in prevention and therapy. *Nutrients* 7: 8199-8226.
9. Guerrero-Romero F, Tamez-Perez HE, Gonzales-Gonzales G (2004) Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. *Diabetes Metab* 30: 253-258.
10. Guerrero-Romero F, Bermudez-Pena C, Rodriguez-Moran M (2011) Severe hypomagnesaemia and low-grade inflammation in metabolic syndrome. *Magnes Res* 24: 45-53.
11. Gunther T (1981) Biochemistry and pathobiochemistry of magnesium. *Artery* 9: 167-187.
12. Hatzistavri LS, Sarafidis PA, Georgianos PI, Tziolas IM, Aroditis CP, et al. (2009) Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. *Am J Hypertens* 22: 1070-1075.
13. Hunger H (2008) Magnesium and the membrane potential. *Trace Elem Electrolyt* 25: 234.
14. Kisters K (2011) Oral magnesium supplementation improves borderline hypertension. *Magnes Res* 24: 17.
15. Kisters K, Spieker C, Tepel M, Zidek W (1993) New data about effects of oral physiological magnesium supplementation on several cardiovascular risk factors (lipids and blood pressure). *Magnes Res* 4: 355-360.
16. Kisters K, Tepel M, Spieker C, Dietl KH, Barenbrock M, et al. (1997) Decreased cellular Mg++ concentrations in a subgroup of hypertensives-cell-models for the pathogenesis of primary hypertension. *J Hum Hypertens* 11: 357-372.
17. Kisters K, Tepel M, Spieker C, Zidek W, Barenbrock M, et al. (1998) Decreased cellular Mg++ concentrations in a subgroup of hypertensives. Membrane model for the pathogenesis of primary hypertension. *Am J Hypertens* 11: 1390-1393.

18. Kisters K, Krefting ER, Barenbrock M, Spieker C, Rahn KH (1999) N⁺ and Mg⁺⁺ contents in smooth muscle cells in spontaneously hypertensive rats. *Am J Hypertens* 12: 648-652.
19. Kisters K, Krefting ER, Hausberg M, Kohnert K, Honig A, et al. (2000) Importance of decreased intracellular phosphate and magnesium concentrations and reduced ATPase activities in SHR. *Magnes Res* 14: 183-188.
20. Kisters K, Wessels F, Tokmak F, Krefting ER, Gremmler B, et al. (2004) Early-onset increased calcium and decreased magnesium concentrations and an increased calcium/magnesium ratio in SHR versus WKY. *Magnes Res* 17: 264-269.
21. Kisters K, Gremmler B, Tokmak F, Cziborra M, Funke C, et al. (2007) Decreased mineral metabolism parameters (magnesium and phosphate) and elevated pulse pressure in hypertension. *Clin Nephrol* 68:130-131.
22. Kisters K, Gremmler B, Hausberg M (2008) Disturbed Mg⁺⁺ transporters in hypertension. *J Hypertens* 12: 2450-2451.
23. Kisters K, Krefting ER, Spieker C, Zidek W, Dietl KH, et al. (1998) Increased magnesium and sodium exchange in vascular smooth muscle cells from SHR. *Clin Sci* 95: 583-587.
24. Kisters K, Wessels F, Nguyen MQ, Mitchell A, Gremmler B, et al. (2012) Magnesium therapy in borderline hypertension. *Trace Elem and Electrolyt* 29: 113-116.
25. Kosch M, Hausberg M, Westermann G, Köneke J, Matzkies F, et al. (2001) Alterations in calcium and magnesium content of red cell membranes in patients with primary hypertension. *Am J Hypertens* 14: 254-258.
26. Manz M, Jung W, Lüderitz B (1997) Effect of magnesium on sustained ventricular tachycardia. *Herz* 22 Suppl 1: 51-55.
27. Porta S, Eppe A, Leitner G, Frise E, Liebmann P, et al. (1994) Impact of stress and triiodothyronine on plasma magnesium fractions. *Life Sci* 55: PL327-332.
28. Porta S, Gell H, Sadjak A, Bacher H, Kisters K (2012) Metabolic changes and hypomagnesaemia. *Trace Elem Electrolyt* 29: 206-211.
29. Rasmussen HS, Aurup P, Goldstein K, McNair P, Mortensen PB, et al. (1989) Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo-controlled study. *Arch Int Med* 149: 1050-1053.
30. Wakaskar RR (2017) Promising Effects of Nanomedicine in Cancer Drug Delivery. *J Drug Target*.
31. Wakaskar RR (2017) General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. *J Drug Target* 18: 1-8.
32. Seelig M, Rosanoff A (2003) The magnesium factor. Penguin Group inc., New York, USA.
33. Von Ehrlich B, Wadepull MC (2003) Erhöhtes Risiko einer diabetischen Retinopathie bei niedrigem Serummagnesium. *Diabetes Stoffwechsel* 12: 285-289.
34. Von Ehrlich B, Barbagallo M, Classen HG, Guerrero-Romero F, Mooren FC, et al. (2014) Die Bedeutung von Magnesium für die Insulinresistenz, metabolisches Syndrom und Diabetes mellitus- Empfehlungen der Gesellschaft für Magnesium-Forschung e.V. *Diabetologie* 9: 96-100.
35. Stepura OB, Martynow AI (2009) Magnesium orotate in severe congestive heart failure (MACH). *Int J Cardiol* 131: 293-295.
36. Geiss KR, Stergiou N, Jester J, Neuenfeld HU, Jester HG (1998) Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease. *Cardiovasc Drugs Ther* 12: 153-156.
37. Resnick LM, Gupta RK, Laragh JH (1984) Intracellular free magnesium in erythrocytes of essential hypertension: relation to blood pressure and serum divalent cations. *Proc Natl Acad Sci* 81: 6511-6515.
38. Resnick LM, Militianu D, Cunnings AJ (1997) Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. *Hypertension* 30: 654-659.
39. Resnick LM, Laragh JH, Sealey JE, Aldemann MH (1983) Divalent cations in essential hypertension: relations between serum ionized calcium, magnesium and plasma renin activity. *N Engl J Med* 309: 888-891.
40. Resnick LM, Gupta RK, Di Fabio B, Barbagallo M, Mann S, et al. (1994) Intracellular ionic consequences of dietary salt loading in essential hypertension. Relation to blood pressure and effects of calcium channel blockade. *J Clin Invest* 94: 1269-1276.
41. Vierling W, Liebscher DH, Micke O, von Ehrlich B, Kisters K (2013) [Magnesium deficiency and therapy in cardiac arrhythmias: recommendations of the German Society for Magnesium Research]. *Dtsch Med Wochenschr* 138: 1165-1171.
42. Ryzen E (1987) Magnesium homeostasis in critically ill patients. *Magnesium* 6: 259-263.
43. Schweigel M, Kolisek M, Nikolic Z, Kuzinski J (2008) Expression and functional activity of Na/Mg exchanger, TRPM 7 and Mag T1 are changed to regulate Mg. *Magnes Res* 21: 118-123.
44. Drews BJ, Ackermann MJ, Funk M, Gibler WB, Kligfield P (2010) Prevention of Torsades de Pointes in hospital settings: a scientific statement from the American heart Association and the American College of Cardiology Foundation. *J Am Coll Cardiol*. 55: 934-947.
45. Gottlieb SS, Fisher ML, Pressel MD, Patten RD, Weinberg M, et al. (1993) Effects of intravenous magnesium sulphate on arrhythmias in patients with congestive heart failure. *Am Heart J* 125: 1645-1650.
46. Iseri LT (1990) Role of magnesium in cardiac tachyarrhythmias. *Am J Cardiol* 65: 47K-50K.
47. Itoh K, Kawasaka N, Nakamura M (1997) The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects. *Br J Nutr* 78: 735-750.
48. Rostron A, Sanni A, Dunning J (2005) Does magnesium prophylaxis reduce the incidence of atrial fibrillation following coronary bypass surgery? *Interact Cardiovasc Thorac Surg* 4: 52-58.
49. Zidek W, Zumkley H (1990) Die Elektrolytfibel. Gustav Fischer Verlag, Stuttgart, New York.
50. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, et al. (2006) ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). *J Am Coll Cardiol* 48: e247-e346.
51. Classen HG, Gröber U, Kisters K (2012) Magnesium Mangel und Arzneimittel. *MMP* 35: 274-280.
52. Gremmler B, Kisters K, Kunert M, Hausberg M, Jegodka R, et al. (2008) Observation of NTproBNP, cardiac output and magnesium in a case of hypertension induced severe heart failure under a combined ACE-inhibitor and candesartan therapy - a case report. *Trace Elem Electrolyt* 25: 235.

Citation: Kisters K, Gremmler B, Schmidt J, Gröber U, Tokmak F (2017) Positive Effect of Magnesium Orotate Therapy in Hypertensive Heart Disease. *Metabolomics* (Los Angel) 7: 195. doi:[10.4172/2153-0769.1000195](https://doi.org/10.4172/2153-0769.1000195)